#161777

TOV-2835EP cell line

Cat. #161777

TOV-2835EP cell line

Cat. #: 161777

Availability: 8-10 weeks

Organism: Human

Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: TOV-2835EP cell line
  • Alternate name: TOV-2835EP
  • Cancer: Lung cancer
  • Research fields: Cancer
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Donor: Grade 3 – Stage III; Mutations: TP53 Exon 8; Carboplatin/Taxol
  • Morphology: Characteristic flattened cobbleston-like appearance. Formed loose aggregates rather than solid spheroids
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from metastases at the omentum (EP) at specific time points at diagnosis and relapse. Cell line exhibits intermediate sensitivity to carboplatin and did not form SC or IP tumors in NRG mice
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 2835 was diagnosed at age 62 with no prior history of cancer. Patient received treatment with Carboplatin and Paclitaxel prior to sampling and sampling was done in

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37° C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  • 10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  • 101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  • 21(20):7697. PMID: 33080952